New publication from Dr. Geoffrey Liu
MBP scientist Dr. Geoffrey Liu and a group of research collaborators have published a new Journal of Thoracic Oncology article entitled 'Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium'.
The study explores the impact of respiratory and cardiometabolic comorbidities on survival rates of non-small cell lung cancer (NSCLC) patients across different stages of the disease.
Dr. Liu and his team used data from 11 different international studies, covering a large pool of NSCLC patients with available comorbidity information. They used Cox models to estimate adjusted hazard ratios (aHRs) for overall survival (OS) and competing risk Grey and Fine models for lung cancer-specific survival (LCSS).
Logistic regression was used to assess the factors associated with surgical resection. They found that the presence of either cardiometabolic or respiratory comorbidities was associated with worse OS in stages I to III NSCLC patients. Patients with respiratory comorbidities were less likely to undergo surgery and had worse LCSS, whereas patients with cardiometabolic comorbidities had a higher risk of death from competing causes.
Overall, Dr. Liu and his team concluded that accounting for comorbidities is essential in the interpretation of clinical trials and clinical management of NSCLC patients.